Showing posts with label chemotherapy research journals. Show all posts
Showing posts with label chemotherapy research journals. Show all posts

Wednesday, 7 June 2017

Osteoblastic Changes During Non-Small Cell Lung Cancer (NSCLC) Treatment

Cell Lung Cancer
Recently, we published an article reporting an example of the potential misinterpretation in the evaluation of osteoblastic changes during tyrosine-kinase inhibitor treatment in metastatic ALKrearranged non-small cell lung cancer.

Bone metastases are common in disseminated NSCLC, occurring in approximately 30% to 40% of patients. In the majority of cases, they present an osteolytic imaging pattern, even though osteoblastic or mixed-type patterns have also been reported in nearly 8% of cases. Generally, in the assessment of objective response to anticancer agents, bone metastases are classified as non-target lesions and therefore “not evaluable” for response.

However, according to the revised Response Evaluation Criteria in Solid Tumors guideline, the appearance of new non-target lesions, including lytic or osteoblastic bone metastases, is a criterion for defining progressive disease. Sometimes, the evaluation of bone lesion response may be challenging and misinterpreted.

Tuesday, 2 May 2017

Clinical Studies on Hormonal Status in Breast Cancer and its Impact on Quality of Life (QOL)

Breast Cancer

Breast cancer is a steroid hormone–dependent tumor. Stratification of patients according to hormone (ER/ PR) receptor status and nodal metastasis is of great therapeutic importance.

In this investigation, we could enroll 79 pre and post-menopausal breast cancer patients voluntarily. We classified these cases into four categories of the combinations of ER/PR positive, negative and mixed statuses.

Their hormone receptor status as determined by immunohistochemistry correlated with therapy regimens like chemotherapy, hormone therapy and QOL responses.

Monday, 20 March 2017

Oncolytic Viral Therapy of Glioblastoma: Will this Soon become a Reality?

Glioblastoma

The first oncolytic virus therapy (talimogene laherparepvec or TVEC) in the U.S. was approved in October 2015 for the treatment of advanced melanoma patients.

Such novel and safer treatments are in active development but not yet available for brain tumors. Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer in adults with median survival of less than 15 months.

Current radiotherapy and chemotherapy regimens not only have failed to significantly benefit high-grade tumor patients, but also are associated with severe long-term side effects that worsen the quality of life.

Monday, 16 January 2017

Osteoblastic Changes During Non-Small Cell Lung Cancer (NSCLC) Treatment

Non-Small Cell Lung Cancer
Recently, we published an article reporting an example of the potential misinterpretation in the evaluation of osteoblastic changes during tyrosine-kinase inhibitor treatment in metastatic ALKrearranged non-small cell lung cancer.

Bone metastases are common in disseminated NSCLC, occurring in approximately 30% to 40% of patients. In the majority of cases, they present an osteolytic imaging pattern, even though osteoblastic or mixed-type patterns have also been reported in nearly 8% of cases. Generally, in the assessment of objective response to anticancer agents, bone metastases are classified as non-target lesions and therefore “not evaluable” for response.

However, according to the revised Response Evaluation Criteria in Solid Tumors guideline, the appearance of new non-target lesions, including lytic or osteoblastic bone metastases, is a criterion for defining progressive disease. Sometimes, the evaluation of bone lesion response may be challenging and misinterpreted.

Wednesday, 24 August 2016

Chronic constipation linked to increased risk of colorectal cancer

Basal Cell Carcinoma:
Basal Cell Carcinoma or BCC is the cancer which is caused due to the unrestricted growth in the skin’s basal cells, i.e., the outermost layer of the skin. BCC appears on the skin in the form of open sores, red patches, pink growths or scars. It lacks the property of metastasis.


colorectal cancer

Benign Neoplasm:
Benign neoplasm is the mass of slow growing localized tumor. The property of metastasis, i.e., to invade surrounding tissues and spread to the distant sites is absent in the benign neoplasm. Therefore, it is said to be non- cancerous. Some kinds of benign neoplasms are adenoma, fibroma, hemangioma and lipoma.
Cancer:
Cancer is a disease in which cells at a particular site grows and proliferate in an abnormal, rapid and unsystematic manner in the body which results in the destruction of the healthy body tissues. Cancer can be Benign or Malignant depending on its property of invasion.